<DOC>
	<DOCNO>NCT00738387</DOCNO>
	<brief_summary>The purpose study determine add ASA404 docetaxel chemotherapy make cancer treatment effective patient locally advanced metastatic non-small cell lung cancer</brief_summary>
	<brief_title>A Study ASA404 Placebo Combination With Docetaxel Second-line Treatment ( Stage IIIb/IV ) Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Vadimezan</mesh_term>
	<criteria>1 . Histologically confirm nonsmall cell carcinoma lung histology . ( Histological cytological specimen must collect via surgical biopsy , brushing , wash core needle aspiration define lesion . Sputum cytology acceptable . ) 2 . Patients progress follow firstline chemotherapy regimen Stage IIIb disease ( malignant pleural effusion pericardial effusion confirm cytologically ) Stage IV disease . Patients receive bevacizumab and/or EGFR inhibitor firstline eligible 3 . Age ≥ 18 year old 4. WHO Performance Status 02 5 . Not applicable per amendment # 2 6 . Central laboratory value within range , define , within 2 week randomization : Absolute neutrophils count ( ANC ) ≥ 2.0 x 109/L Platelets ≥ 100 x109/L Hemoglobin ≥ 10 g/dL Serum creatinine ≤ 1.5 x ULN Serum bilirubin ≤ 1.5 x ULN Aspartate transaminase ( AST ) alanine transaminase ( ALT ) ≤2.5 x ULN ( ≤5 x ULN liver metastasis ) International Normalized Ratio ( INR ) Prothrombin Time ( PT ) ≤1.5 x ULN Electrolyte value ( sodium , potassium , calcium , magnesium ) within ≥1 x LLN ≤1 x ULN . Patients correct electrolyte value eligible Females childbearing potential must negative serum pregnancy test ( confirmation negative urine pregnancy test within 72 hour prior initial dose ) . Any female presenting positive borderline pregnancy test may undergo gynecological exam ultra sound rule pregnancy find negative may include trial . 7 . Life expectancy ≥ 12 week 8 . Written inform consent obtain accord local guideline 1 . Patients CNS metastasis ( patient clinical sign CNS metastases must CT MRI brain perform rule CNS metastasis order eligible study participation . Patients brain metastasis surgically remove irradiated residual disease confirm image allow ) . 2 . Patients concurrent malignancy , history prior malignancy within past two year , except basal cell squamous cell skin cancer , carcinoma situ cervix , treat early stage ( T1a ) prostate cancer treat early stage ( DCIS LCIS ) breast cancer . 3 . Radiotherapy ≤ 2 week prior randomization . Patients must recover acute radiotherapyrelated toxicity . 4 . Major surgery must complete 4 week prior start study treatment . Major surgery define investigator 's discretion . Insertion vascular access device consider major minor surgery . Patients must recover acute surgeryrelated complication . 5 . Treatment prior anticancer therapy ≤ 3 week prior randomization ( ≤ 6 week bevacizumab , mitomycin nitrosoureas ) 6 . Concurrent use investigational agent patient receive investigational agent ≤ 4 week prior randomization 7 . Prior treatment docetaxel NSCLC locally advance metastatic firstline set 8 . Prior treatment VDAs tumor VDAs 9 . Any medical condition result ≥ CTC grade 2 dyspnea 10 . Patients systolic BP &gt; 160 mm Hg and/or diastolic BP &gt; 90 mm Hg medication hypertension 11 . Patients recent hemoptysis associate NSCLC ( &gt; 1 teaspoon single episode within 4 week ) 12 . Patients one following : Patients long QT syndrome Patients Baseline 12lead ECG QTcF &gt; 450 msec men &gt; 470 msec woman use Fridericia [ QTcF formula ] measurement determine per central ECG evaluation report Congestive heart failure ( NY Heart Association class III IV ) Patients myocardial infarction within 12 month start study treatment implant cardiac pacemaker Unstable poorly control angina pectoris , include Prinzmetal variant angina pectoris History poorlycontrolled hypertension poor compliance antihypertensive regimen History sustain ventricular tachycardia Presence atrial tachycardia ( e.g. , atrial fibrillation , atrial flutter , multifocal atrial tachycardia , supraventricular tachycardia ) effectively ratecontrolled History ventricular fibrillation Torsades de Pointes ( TdP ) Right bundle branch block ( RBBB ) either leave anterior hemiblock leave posterior hemiblock ( bifasicular block ) Bradycardia define heart rate &lt; 50 beat per minute [ For China : Patients older 70 year evidence myocardial ischemia coronary artery angiography cardiac radionucleotide image examination ] [ For China : Patients LVEF &lt; =40 % ] Any clinically significant cardiac abnormality assess investigator 13 . Patients currently receive treatment medication potential prolong QT interval know risk cause Torsades de Pointes ( See Section 6.8.5.1 Appendix 2 ) either safely discontinue switch different medication prior start study drug administration must discuss approve Novartis Global Clinical team prior randomization . 14 . Known allergy hypersensitivity docetaxel drug formulate polysorbate 80 15 . Peripheral sensory neuropathy functional impairment ( CTC grade 2 neuropathy , regardless causality ) 16 . Pregnant breast feeding female • Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive hCG laboratory test ( &gt; 5 mIU/ml ) 17 . Women child bear potential sexually active male , unwilling unable use require highly effective method ( ) contraception sex receive treatment least 6 month discontinuation study treatment . ( Adequate form contraception include IUD , oral depot contraceptive barrier method plus spermicide . ) • Oral , implantable , injectable contraceptive may affect cytochrome P450 interaction take docetaxel therefore consider effective contraceptive method study use single agent . Therefore , highly recommended concomitant barrier method use oral , implantable , injectable contraceptive . The investigator shall counsel patient accordingly . Women childbearing potential must negative pregnancy test ( serum urine ) 72 hour prior administration study treatment . For list substrate human liver microsomal P450 enzyme , visit website ( http : //medicine.iupui.edu/flockhart/ ) 18 . Concurrent severe and/or uncontrolled medical disease ( i.e . uncontrolled diabetes , chronic renal disease , chronic liver disease , confirm diagnosis HIV infection active uncontrolled infection ) . 19 . Significant neurologic psychiatric disorder could compromise participation study 20 . Patient unwilling unable comply protocol 21 . Patients receive fulldose therapeutic oral parenteral anticoagulation ineligible . Patients receive thrombolytic therapy within 10 day start also ineligible . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Tumor vascular disrupting agent</keyword>
	<keyword>VDA</keyword>
	<keyword>ASA404</keyword>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>NSCLC</keyword>
</DOC>